| アブストラクト | INTRODUCTION: As asthma medications are frequently prescribed for children, knowledge of the safety of these drugs in the paediatric population is important. Although spontaneous reports cannot be used to prove causality of adverse events, they are important in the detection of safety signals. OBJECTIVE: Our objective was to provide an overview of adverse drug events associated with asthma medications in children from a spontaneous reports database and to identify new signals. METHODS: Spontaneous reports concerning asthma drugs were obtained from EudraVigilance, the European Medicine Agency's database for suspected adverse drug reactions. For each drug-event combination, we calculated the proportional reporting ratio (PRR) in the study period 2011-2017. Signals in children (aged 0-17 years) were compared with signals in the whole population. Analyses were repeated for different age categories, by sex and by therapeutic area. RESULTS: In total, 372,345 reports in children resulted in 385 different signals concerning asthma therapy. The largest group consisted of psychiatric events (65 signals). Only 30 signals were new, with seven, including herpes viral infections, associated with omalizumab. Stratification by age, sex and therapeutic area provided additional new signals, such as hypertrichoses with budesonide and encephalopathies with theophylline. Of all signals in children, 60 (16%) did not appear in the whole population. CONCLUSIONS: The majority of signals regarding asthma therapy in children were already known, but we also identified new signals. We showed that signals can be masked if age stratification is not conducted. Further exploration is needed to investigate the risk and causality of the newly found signals. |
|---|
| ジャーナル名 | Drug safety |
|---|
| Pubmed追加日 | 2019/10/17 |
|---|
| 投稿者 | Baan, Esme J; de Smet, Veronique A; Hoeve, Christina E; Pacurariu, Alexandra C; Sturkenboom, Miriam C J M; de Jongste, Johan C; Janssens, Hettie M; Verhamme, Katia M C |
|---|
| 組織名 | Department of Medical Informatics, Erasmus Medical Centre, Erasmus University,;Dr. Molewaterplein 50, 3015 GE, Rotterdam, The Netherlands. e.baan@erasmusmc.nl.;Department of Pharmacy, Ghent University Hospital, Ghent, Belgium.;Dr. Molewaterplein 50, 3015 GE, Rotterdam, The Netherlands.;Julius Global Health, University Medical Centre Utrecht, Utrecht, The;Netherlands.;Department of Pediatrics/Respiratory Medicine, Erasmus University/Sophia;Children's Hospital, Rotterdam, The Netherlands.;Department of Infection Control and Epidemiology, OLV Hospital, Aalst, Belgium. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/31617080/ |
|---|
